Shingles Vaccine Market Size Projected To Increase From $6.37 Billion To $10.96 Billion During The Forecast Period
Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Shingles Vaccine Market Size Outlook: How Fast Will Revenue Grow Through 2030?
The shingles vaccine market has experienced significant expansion over the past several years, with projections showing an increase from $5.55 billion in 2025 to $6.37 billion in 2026, reflecting a compound annual growth rate (CAGR) of 14.8%. This historical growth has been driven by factors such as the constrained supply of shingles vaccines, a dependence on live attenuated formulations, the expanding elderly demographic, a higher prevalence of herpes zoster cases, and a growing public understanding of the advantages associated with immunization.
The shingles vaccine market is projected to experience significant expansion over the coming years, with an anticipated value of $10.96 billion by 2030, driven by a compound annual growth rate (CAGR) of 14.5%. This forecasted growth is fueled by the development of recombinant and subunit vaccines, the broadening of both public and private vaccination initiatives, a growing reliance on online and retail pharmacy channels for distribution, increased government and healthcare efforts aimed at immunizing the elderly, and the incorporation of digital health monitoring to improve vaccine adherence. Key trends shaping this period include a higher uptake of recombinant and subunit shingles vaccines, greater awareness about shingles prevention among older adults, the expansion of vaccination programs via hospitals and retail pharmacies, the rise of online pharmacies and e-commerce for vaccine distribution, and a targeted focus on age-specific immunization strategies for individuals aged 50 and older.
Download A Free Sample Report For Comprehensive Market Insights:
Shingles Vaccine Market Industry Drivers: What Is Driving Revenue Growth?
The growth of the shingles vaccine market is anticipated to be driven forward by the rising number of vaccination initiatives. These initiatives are organized public health efforts aimed at the systematic delivery of vaccines to populations to curb the spread of infectious diseases. A growing focus on preventive healthcare, which encourages more individuals to seek vaccination as a means of avoiding illness, has led to an increase in the number of such programs. By boosting public awareness and improving accessibility, vaccination initiatives facilitate the uptake of the shingles vaccine, particularly benefiting older adults and those at higher risk. Through the encouragement of widespread and timely immunization, they help lower the incidence of shingles and its associated complications, thereby enhancing community health. In July 2025, for example, the World Health Organization—a Switzerland-based intergovernmental body—reported that global coverage for the first dose of the human papillomavirus (HPV) vaccine among girls rose from 27% in 2023 to 31% in 2024. Consequently, the expansion of vaccination programs is propelling the shingles vaccine market forward.
Shingles Vaccine Market Segment Outlook: Which Categories Are Expanding The Fastest?
The shingles vaccine market covered in this report is segmented –
1) By Vaccine Type: Live Attenuated Vaccine, Recombinant Vaccine, Subunit Vaccine
2) By Product: Shingrix, Zostavax, Skyzoster
3) By Age Group: 50-59 Years, 60-69 Years, 70 Years And Above
4) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies
5) By End User: Hospitals, Clinics, Pharmacies
Subsegments:
1) By Live Attenuated Vaccine: Virus Strain A, Virus Strain B, Virus Strain C
2) By Recombinant Vaccine: Recombinant Protein Vaccine, Recombinant Vector Vaccine, Recombinant Deoxyribonucleic Acid Vaccine
3) By Subunit Vaccine: Protein Subunit Vaccine, Conjugate Subunit Vaccine
Shingles Vaccine Market Growth Trends: What Is Influencing The Future Outlook?
Key players in the shingles vaccine market are concentrating on the creation of advanced vaccine formulations, particularly recombinant adjuvanted types, aimed at amplifying immune responses and delivering durable protection against shingles. These vaccines are produced using lab-generated viral proteins paired with adjuvants—substances that stimulate a stronger and more prolonged immune defense. A notable example occurred in April 2023, when GlaxoSmithKline Pharmaceuticals Ltd., a pharmaceutical firm based in India, introduced Shingrix, a shingles vaccine. Administered as two intramuscular doses to individuals aged 50 and over, Shingrix is a non-live, recombinant adjuvanted subunit vaccine specifically formulated to prevent shingles (herpes zoster) and its associated complication, post-herpetic neuralgia. Achieving over 90% efficacy, this vaccine ensures robust and enduring immunity that persists for at least a decade, proving effective for both older adults and those with compromised immune systems.
Shingles Vaccine Market Key Companies And Competitive Benchmarking
Major companies operating in the shingles vaccine market are Merck & Co. Inc., GSK plc, SK bioscience, Pfizer Inc, GeneOne Life Science, Curevo Inc, Novavax Inc
Access The Complete Shingles Vaccine Market Report:
Shingles Vaccine Market Leading Geography: Which Region Generates The Most Revenue?
North America was the largest region in the shingles vaccine market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the shingles vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
